Clinical Trials
27 trialsTucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor.
Sun Yat-sen University
Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
Shengjing Hospital
FATIMA
Africa Middle East Cancer Intergroup
Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer
Guangdong Provincial People's Hospital
Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery
Gruppo Italiano Mammella (GIM)
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Amsterdam UMC, location VUmc
Pyrotinib Combined With Trastuzumab Plus Aromatase Inhibitor in Treatment of Breast Cancer
Fuzhou General Hospital
MEGA
Instituto Nacional de Cancer, Brazil
Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Pyrotinib
Peking Union Medical College Hospital
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
Samsung Medical Center
STEP
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NEOADAPT
Midwestern Regional Medical Center
BETTER
Sun Yat-sen University
Cimicifuga
Irmandade da Santa Casa de Misericordia de Sao Paulo
FRIEND
ChineseAMS
Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD
National University Hospital, Singapore
FEVEX
Consorzio Oncotech
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
Organisation for Oncology and Translational Research
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
National Cancer Institute (NCI)
Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy
National Cancer Institute (NCI)
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
National Cancer Institute (NCI)
Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer
ChineseAMS
Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer
Tianjin Medical University
Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
LEANEX
Fudan University